MX2021010297A - Inhibidores de calicreina plasmatica humana. - Google Patents

Inhibidores de calicreina plasmatica humana.

Info

Publication number
MX2021010297A
MX2021010297A MX2021010297A MX2021010297A MX2021010297A MX 2021010297 A MX2021010297 A MX 2021010297A MX 2021010297 A MX2021010297 A MX 2021010297A MX 2021010297 A MX2021010297 A MX 2021010297A MX 2021010297 A MX2021010297 A MX 2021010297A
Authority
MX
Mexico
Prior art keywords
plasma kallikrein
human plasma
compounds
kallikrein inhibitors
inhibitors
Prior art date
Application number
MX2021010297A
Other languages
English (en)
Inventor
Pravin L Kotian
Yarlagadda S Babu
Weihe Zhang
V Satish Kumar
Lakshminarayana Vogeti
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MX2021010297A publication Critical patent/MX2021010297A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Se describen compuestos de la Fórmula I y sales de éstos aceptables desde el punto de vista farmacéutico. Los compuestos son inhibidores de calicreína plasmática. También se proporcionan composiciones farmacéuticas que comprenden al menos un compuesto de la invención, y métodos que implican el uso de los compuestos y las composiciones de la invención en el tratamiento y la prevención de enfermedades y afecciones caracterizadas por la acción no deseada de la calicreína plasmática.
MX2021010297A 2015-10-01 2018-03-28 Inhibidores de calicreina plasmatica humana. MX2021010297A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562235754P 2015-10-01 2015-10-01

Publications (1)

Publication Number Publication Date
MX2021010297A true MX2021010297A (es) 2021-10-22

Family

ID=58424336

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018003930A MX2018003930A (es) 2015-10-01 2016-09-30 Inhibidores de calicreína plasmática humana.
MX2021010297A MX2021010297A (es) 2015-10-01 2018-03-28 Inhibidores de calicreina plasmatica humana.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018003930A MX2018003930A (es) 2015-10-01 2016-09-30 Inhibidores de calicreína plasmática humana.

Country Status (31)

Country Link
US (3) US10562850B2 (es)
EP (2) EP3355890B1 (es)
JP (2) JP6916171B2 (es)
KR (1) KR20180058815A (es)
CN (2) CN108289893B (es)
AR (1) AR106241A1 (es)
AU (2) AU2016330926B2 (es)
CA (1) CA2999164A1 (es)
CO (1) CO2018004572A2 (es)
CY (1) CY1124907T1 (es)
DK (2) DK4019022T3 (es)
EA (2) EA202191548A1 (es)
ES (1) ES2905401T3 (es)
FI (1) FI4019022T3 (es)
HK (1) HK1254865A1 (es)
HR (1) HRP20220059T1 (es)
HU (1) HUE057106T2 (es)
IL (3) IL291268B2 (es)
LT (2) LT4019022T (es)
MA (1) MA43052B1 (es)
MD (1) MD3355890T2 (es)
MX (2) MX2018003930A (es)
MY (1) MY198346A (es)
PH (1) PH12018500678A1 (es)
PL (1) PL3355890T3 (es)
PT (2) PT4019022T (es)
RS (1) RS62807B1 (es)
SG (1) SG10202003705WA (es)
SI (1) SI3355890T1 (es)
TW (2) TWI734702B (es)
WO (1) WO2017059178A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4019022T (pt) * 2015-10-01 2024-03-11 Biocryst Pharm Inc Inibidores da calicreína plasmática humana
EP3661922A1 (en) 2017-08-04 2020-06-10 Dyax Corp. Inhibitors of plasma kallikrein and uses thereof
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
CN110938077B (zh) * 2019-12-25 2021-04-27 武汉九州钰民医药科技有限公司 合成Avapritinib的方法
TW202144331A (zh) * 2020-02-13 2021-12-01 德商百靈佳殷格翰國際股份有限公司 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物
CN116444485B (zh) * 2023-03-30 2024-01-23 广西中医药大学 吡啶基取代不对称脲的非金属催化、免柱层析合成方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
LU86084A1 (fr) 1985-09-20 1987-04-02 Faco Sa Apparei de massage electrique
US5102417A (en) 1985-11-07 1992-04-07 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1990013332A1 (en) 1989-05-11 1990-11-15 Cedars-Sinai Medical Center Stent with sustained drug delivery
EP0470246B1 (en) 1990-02-28 1995-06-28 Medtronic, Inc. Intralumenal drug eluting prosthesis
US5429634A (en) 1993-09-09 1995-07-04 Pdt Systems Biogenic implant for drug delivery and method
US5419760A (en) 1993-01-08 1995-05-30 Pdt Systems, Inc. Medicament dispensing stent for prevention of restenosis of a blood vessel
WO1995007986A1 (en) * 1993-09-14 1995-03-23 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
AU4064597A (en) * 1996-08-16 1998-03-06 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
PL204263B1 (pl) * 2001-09-21 2009-12-31 Bristol Myers Squibb Co Pochodna 1H-pirazolo[3,4-c]pirydyny i jej zastosowanie oraz kompozycja farmaceutyczna i jej zastosowanie
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
US6770729B2 (en) 2002-09-30 2004-08-03 Medtronic Minimed, Inc. Polymer compositions containing bioactive agents and methods for their use
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
MXPA05010444A (es) * 2003-04-03 2005-11-04 Merck Patent Gmbh Compuestos de carbonilo.
DE10315377A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Carbonylverbindungen
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
DE102004014945A1 (de) * 2004-03-26 2005-10-13 Merck Patent Gmbh Prolinylderivate
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
US20140350034A1 (en) 2012-01-27 2014-11-27 Novartis Ag Aminopyridine derivatives as plasma kallikrein inhibitors
TWI510481B (zh) 2012-06-04 2015-12-01 Actelion Pharmaceuticals Ltd 苯并咪唑脯胺酸衍生物
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
US9718840B2 (en) * 2014-01-14 2017-08-01 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative
CN106257976B (zh) * 2014-03-07 2021-02-02 拜奥克里斯特制药公司 人类血浆激肽释放酶抑制剂
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
BR112017018092A2 (pt) 2015-02-27 2018-04-10 Verseon Corp composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
PT4019022T (pt) * 2015-10-01 2024-03-11 Biocryst Pharm Inc Inibidores da calicreína plasmática humana

Also Published As

Publication number Publication date
CY1124907T1 (el) 2023-01-05
JP2021169505A (ja) 2021-10-28
DK3355890T3 (da) 2022-01-03
CO2018004572A2 (es) 2018-10-31
HRP20220059T1 (hr) 2022-04-15
IL291268B1 (en) 2023-08-01
IL281066A (en) 2021-04-29
US20220098151A1 (en) 2022-03-31
PH12018500678A1 (en) 2018-10-01
MA43052B1 (fr) 2021-11-30
WO2017059178A1 (en) 2017-04-06
AR106241A1 (es) 2017-12-27
US20180362458A1 (en) 2018-12-20
PL3355890T3 (pl) 2022-02-21
JP2018529721A (ja) 2018-10-11
TW201716381A (zh) 2017-05-16
HUE057106T2 (hu) 2022-04-28
MY198346A (en) 2023-08-28
MD3355890T2 (ro) 2022-03-31
IL258104B (en) 2021-03-25
CN108289893B (zh) 2022-04-12
CN108289893A (zh) 2018-07-17
SI3355890T1 (sl) 2022-04-29
SG10202003705WA (en) 2020-06-29
AU2016330926A1 (en) 2018-04-26
PT3355890T (pt) 2022-01-19
IL291268A (en) 2022-05-01
ES2905401T3 (es) 2022-04-08
IL291268B2 (en) 2023-12-01
IL258104A (en) 2018-05-31
HK1254865A1 (zh) 2019-07-26
EA201890862A1 (ru) 2018-10-31
EA202191548A1 (ru) 2021-09-02
EA038492B1 (ru) 2021-09-07
PT4019022T (pt) 2024-03-11
DK4019022T3 (en) 2024-02-19
EP4019022B1 (en) 2024-01-31
JP7431778B2 (ja) 2024-02-15
JP6916171B2 (ja) 2021-08-11
TWI734702B (zh) 2021-08-01
EP4019022A1 (en) 2022-06-29
CA2999164A1 (en) 2017-04-06
LT4019022T (lt) 2024-03-25
FI4019022T3 (fi) 2024-04-19
BR112018005843A2 (pt) 2018-10-16
US20200361867A1 (en) 2020-11-19
US10562850B2 (en) 2020-02-18
MX2018003930A (es) 2018-09-18
RS62807B1 (sr) 2022-02-28
US11066360B2 (en) 2021-07-20
TWI796714B (zh) 2023-03-21
AU2021201924A1 (en) 2021-04-29
EP3355890A4 (en) 2019-04-24
EP3355890A1 (en) 2018-08-08
US11807605B2 (en) 2023-11-07
CN114591212A (zh) 2022-06-07
AU2016330926B2 (en) 2021-04-29
TW202136212A (zh) 2021-10-01
IL281066B (en) 2022-04-01
AU2021201924B2 (en) 2022-10-13
KR20180058815A (ko) 2018-06-01
LT3355890T (lt) 2021-12-27
MA43052A (fr) 2021-05-12
EP3355890B1 (en) 2021-11-10

Similar Documents

Publication Publication Date Title
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
MX2017000450A (es) Compuestos terapeuticos inhibidores.
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
MX2018005041A (es) Compuestos para tratar la esclerosis lateral amiotrofica.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MX368903B (es) Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
WO2016004413A3 (en) Gls1 inhibitors for treating disease
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12017501668A1 (en) Bace1 inhibitors
WO2016112304A8 (en) Furoquinolinediones as inhibitors of tdp2
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2019014773A (es) Inhibidores de ccl2.
EA202091668A3 (ru) Ингибиторы калликреина плазмы человека